---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026177"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:17:20.352282+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atossa Q3 2022: cash $117.5M, no revenue; FDA authorizes Phase 2 endoxifen study

## Summary
- Cash, cash equivalents and restricted cash $117.5M as of Sep 30, 2022; no revenue in Q3.
- Operating expenses $8.2M in Q3 2022, up 59% YoY; R&D $5.2M (+134%) on higher trial costs.
- FDA authorized Phase 2 neoadjuvant (Z)-endoxifen for ER+/HER2- breast cancer; enrollment expected Q4 2022.
- Invested in privately-held Dynamic Cell Therapies (CAR-T); paid $300K for exclusive negotiation right.
- Completed dosing in Parts B and C of Phase 1/2a AT-H201 trial for lung injury from cancer treatment.

## SEC filing metadata
- accession: 0001437749-22-026177
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/0001437749-22-026177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/atos20221103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026177
- JSON: https://secwatch.observer/filing/0001437749-22-026177.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026177.txt

## Key facts
- Earnings Releases
  ATOSSA THERAPEUTICS, INC. reported the fiscal quarter ended September 30, 2022 results: revenue no source of revenue.
  - Period: the fiscal quarter ended September 30, 2022
  - Revenue: no source of revenue
  - Result: reported results
  source text: Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774922026177/0001437749-22-026177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.